Y. Paul Goldberg - Net Worth and Insider Trading
Y. Paul Goldberg Net Worth
The estimated net worth of Y. Paul Goldberg is at least $270,000 dollars as of 2024-11-10. Y. Paul Goldberg is the VP of Clinical Development of Xenon Pharmaceuticals Inc and owns about 6,000 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $270,000. Details can be seen in Y. Paul Goldberg's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Y. Paul Goldberg has not made any transactions after 2015-09-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Y. Paul Goldberg
Y. Paul Goldberg Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Y. Paul Goldberg owns 1 companies in total, including Xenon Pharmaceuticals Inc (XENE) .
Click here to see the complete history of Y. Paul Goldberg’s form 4 insider trades.
Insider Ownership Summary of Y. Paul Goldberg
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc | 2015-09-24 | VP & Clinical Development |
Y. Paul Goldberg Latest Holdings Summary
Y. Paul Goldberg currently owns a total of 1 stock. Y. Paul Goldberg owns 6,000 shares of Xenon Pharmaceuticals Inc (XENE) as of September 24, 2015, with a value of $270,000.
Latest Holdings of Y. Paul Goldberg
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc | 2015-09-24 | 6,000 | 45.00 | 270,000 |
Holding Weightings of Y. Paul Goldberg
Y. Paul Goldberg Form 4 Trading Tracker
According to the SEC Form 4 filings, Y. Paul Goldberg has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the sale of 22,149 shares on September 24, 2015, which brought Y. Paul Goldberg around $196,683.
Insider Trading History of Y. Paul Goldberg
- 1
Y. Paul Goldberg Trading Performance
Y. Paul Goldberg Ownership Network
Ownership Network List of Y. Paul Goldberg
Ownership Network Relation of Y. Paul Goldberg
Y. Paul Goldberg Owned Company Details
What does Xenon Pharmaceuticals Inc do?
Who are the key executives at Xenon Pharmaceuticals Inc?
Y. Paul Goldberg is the VP & Clinical Development of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include SVP Bus. & Corp. Development Sherrington Robin , director & PRESIDENT & CEO Ian Mortimer , and Chief Medical Officer Christopher John Kenney .
Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary
Over the past 18 months, Y. Paul Goldberg made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 26,576 shares made by Gary Patou , a net sale of 131,245 shares made by Simon N. Pimstone , and a net sale of 31,655 shares made by Ian Mortimer .
In summary, during the past 3 months, insiders sold 0 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 236,705 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 236,705 shares.
Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenon Pharmaceuticals Inc Insider Transactions
Y. Paul Goldberg Mailing Address
Above is the net worth, insider trading, and ownership report for Y. Paul Goldberg. You might contact Y. Paul Goldberg via mailing address: C/o Xenon Pharmaceuticals Inc., 200 - 3650 Gilmore Way, Burnaby A1 V5g4w8.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
